High dose total marrow irradiation (TMI) does not increase long-term toxicity of myeloablative fludarabine/busulfan (FluBu4) conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT).
High dose total marrow irradiation (TMI) does not increase long-term toxicity of myeloablative fludarabine/busulfan (FluBu4) conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT). Eur J Haematol. 2024 Jul; 113(1):110-116.
PMID: 38566462Corrigendum: Absolute oxygen-guided radiation therapy improves tumor control in three preclinical tumor models.
Corrigendum: Absolute oxygen-guided radiation therapy improves tumor control in three preclinical tumor models. Front Med (Lausanne). 2023; 10:1339872.
PMID: 38116039Absolute oxygen-guided radiation therapy improves tumor control in three preclinical tumor models.
Absolute oxygen-guided radiation therapy improves tumor control in three preclinical tumor models. Front Med (Lausanne). 2023; 10:1269689.
PMID: 37904839Editorial: Total marrow irradiation.
Editorial: Total marrow irradiation. Front Oncol. 2023; 13:1240530.
PMID: 37538119An Efficient Multi-Scale Fusion Network for 3D Organs at Risk (OARs) Segmentation.
An Efficient Multi-Scale Fusion Network for 3D Organs at Risk (OARs) Segmentation. Annu Int Conf IEEE Eng Med Biol Soc. 2023 07; 2023:1-4.
PMID: 38082949A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
PMID: 35851593Impact of respiratory motion on lung dose during total marrow irradiation.
Impact of respiratory motion on lung dose during total marrow irradiation. Front Oncol. 2022; 12:924961.
PMID: 36330489Knowledge-based planning for multi-isocenter VMAT total marrow irradiation.
Knowledge-based planning for multi-isocenter VMAT total marrow irradiation. Front Oncol. 2022; 12:942685.
PMID: 36267964A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
Tran MC, Hasan Y, Wang AY, Yenice KM, Partouche J, Stock W, Larson RA, Kosuri S, LaBelle JL, Kline J, Riedell PA, Artz AS, Weichselbaum RR, Bishop MR, Aydogan B, Liu H. A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2022 Jul 18.
PMID: 35851593Subacute thyroiditis during the COVID-19 pandemic: a prospective study.
View All Publications
Subacute thyroiditis during the COVID-19 pandemic: a prospective study. J Endocrinol Invest. 2022 Apr; 45(4):865-874.
PMID: 35023078
Bulent Aydogan, PhD
-
Professor of Radiation and Cellular Oncology
Committee on Medical Physics - Websites: Research Network Profile
- Contact: baydogan@uchicago.edu
- Graduate Programs: Medical Physics, UChicago Biosciences, PhD Program in Medical Physics